ClinicalTrials.Veeva

Menu

Non-interventional Study -Observe Treatment Efficacy in Maintaining Symptoms Control in Schizophrenia With Seroquel XR

AstraZeneca logo

AstraZeneca

Status

Completed

Conditions

Schizophrenia

Study type

Observational

Funder types

Industry

Identifiers

NCT00750087
NIS-NRO-SER-2008/1

Details and patient eligibility

About

the primary purpose of the study is to observe symptoms control in schizophrenia for 6 months in patients treated with Seroquel XR.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Enrollment

578 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients will have a diagnosis of schizophrenia , as defined by DSM-IV-TR and their symptoms are controlled with Seroquel XR therapy started approximately 1 month before
  • All eligible patients will be included in the protocol provided they will receive detailed information in advance and will sign consent to grant access to their own data collected during this programme.

Exclusion criteria

  • All the patients who have a known hypersensitivity to Seroquel XR/quetiapine or any of its excipients will not be included in this study.
  • As per valid Romanian SmPC, concomitant medication, that could result in drug interactions and could jeopardise patient safety will be carefully considered before having the patient enrolled.

Trial design

578 participants in 1 patient group

1
Description:
Schizophrenia patients stabilized on Seroquel XR

Trial contacts and locations

33

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems